How many clinical trials are tracked for Waldenstroms Macroglobulinemia?

18 trials are tracked, 2 with published results.

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine OB/GYN & Women's Health Orthopedics & Sports Medicine Genetics & Precision Medicine Radiology & Imaging Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Dermatology Urology Emergency Medicine Ophthalmology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Questions

Text Size

Waldenstroms Macroglobulinemia

Part of Plasma cell dyscrasias

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Waldenstroms Macroglobulinemia

18 trials tracked for Waldenstroms Macroglobulinemia: 2 in phase 3 or 4 and 2 with published results. The most-cited published study has 348 citations.

18Trials tracked

2Phase 3 & 4

0Recruiting

2With published results

Phase distribution

Phase 3 2 Phase 2 14 Phase 1 2

Phase 3 Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia Completed · 348 cited
Phase 3 A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM) Completed · 38 cited
Phase 2 LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia Completed
Phase 2 Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia Completed
Phase 2 A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma Completed
Phase 2 Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia Completed

Show 12 more trials

Phase 2 Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia Completed
Phase 2 Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia Completed
Phase 2 Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing Completed
Phase 2 Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia Completed
Phase 2 Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401 Completed
Phase 2 Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia Completed
Phase 2 Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia Completed
Phase 2 Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM) Completed
Phase 2 Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies Completed
Phase 2 Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients Completed
Phase 1 Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies Completed
Phase 1 Study of MLN8237 in Participants With Advanced Hematological Malignancies Completed

Showing the 18 most-cited and recently-updated of 18 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.